Oral administration of Butyrivibrio fibrisolvens, a butyrate-producing bacterium, decreases the formation of aberrant crypt foci in the colon and rectum of mice

Journal of Nutrition

Volumn 135, Issue 12, 2005, Pages 2878-2883

  Ohkawara, Sou ^a   Furuya, Hideki ^a   Nagashima, Kousuke ^a   Asanuma, Narito ^a   Hino, Tsuneo ^a  

^a MEIJI UNIVERSITY   (Japan)

Author keywords

Butyrate; Butyrivibrio fibrisolvens; Colon cancer; Intestinal bacteria; Probiotic

Indexed keywords

1,2 DIMETHYLHYDRAZINE; BETA GLUCURONIDASE; BUTYRIC ACID; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL STRAIN; BACTERIUM; BUTYRIVIBRIO FIBRISOLVENS; CELL FREE SYSTEM; COLON; COLONY FORMING UNIT; COLORECTAL CANCER; CONTROLLED STUDY; CRYPT CELL; ENZYME ACTIVITY; FECES MICROFLORA; MALE; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; RECTUM; SPLEEN;

ANIMALIA; BACTERIA (MICROORGANISMS); BUTYRIVIBRIO FIBRISOLVENS;

EID: 31544446284     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/135.12.2878     Document Type: Article

References (53)

1. Cummings JH, MacFarlane GT. The colonic flora, fermentation and large bowel digestive function. In: Philips SF, Pemberton JH, Shorter RG, editors. The large intestine: physiology, pathophysiology, and disease. New York: Raven Press; 1991. p. 51-91.
2. Szylit O, Andrieux C. Physiological and pathophysiological effects of carbohydrate fermentation. World Rev Nutr Diet. 1993;74:88-122.
3. Cummings JH. Short chain fatty acids in the human colon. Gut. 1981;22:773-9.
4. Delzenne NM, Roberfroid MR. Physiological effects of non-digestible oligosaccharides. Lebens-Wiss Technol. 1994;27:1-6.
5. Roediger WEW. The colonic epithelium in ulcerative colitis: an energy deficient disease? Lancet. 1980;4:712-5.
6. Hague A, Singh B, Paraskeva C. Butyrate acts as a survival factor for colonic epithelial cells: further fuel for the in vivo versus in vitro debate. Gastroenterology. 1997;112:1036-40.
7. Parker SL, Tong T, Bolden S, Wong PA. Cancer statistics, 1996. CA Cancer J Clin. 1996;46:5-27.
8. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon, FEMS Microbiol Lett. 2002;217:133-9.
9. Topping DL Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001;81:1031-64.
10. Simpson JW. Diets and large intestinal disease in dogs and cats. J Nutr. 1998;128:2717S-22.
11. Grieshop CM, Flickinger EA, Fahey GC Jr. Oral administration of arabinogalactan affects immune status and fecal microbial populations in dogs. J Nutr. 2002;132:478-82.
12. Mortensen PB, Clausen MR. Short chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol. 1996;31 Suppl. 216:132-48.
13. Perrin P, Pierre F, Patry Y, Champ M, Berreur M, Pradal G, Bornet F, Meflah K, Menanteau J. Only fibres promoting a stable butyrate producing colonic ecosystem decrease the rate of aberrant crypt foci in rats. Gut. 2001;48:53-61.
14. Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989;66:365-78.
15. Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, Kurata S. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int. 2003;45:86-90.
16. Nakanishi S, Kataoka K, Kuwahara T, Ohnishi Y. Effects of high amylose maize starch and Clostridium butyricum on metabolism in colonic microbiota and formation of azoxymethane-induced aberrant crypt foci in the rat colon. Microbiol Immunol. 2003;47:951-8.
17. Araki Y, Fujiyama Y, Andoh A, Koyama S, Kanauchi O, Bamba T. The dietary combination of germinated barley foodstuff plus Clostridium butyricum suppresses the dextran sulfate sodium-induced experimental colitis in rats. Scand J Gastroenterol. 2000;35:1060-7.
18. Okamoto T, Sasaki M, Tsujikawa T, Fujiyama Y, Bamba T, Kusunoki M. Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. J Gastroenterol. 2000;35:341-6.
19. Stewart CS, Flint HJ, Bryant MP. The rumen bacteria. In: Hobson PN, Stewart CS, editors. The rumen microbial ecosystem. 2nd ed. New York: Blackie Academic and Professional; 1997. p. 10-72.
20. Kepler CR, Hirons KP, McNeil JJ, Tove SB. Intermediates and products of the biohydrogenation of linoleic acid by Butyrivibrio fibrisolvens. J Biol Chem. 1966;241:1350-4.
21. Wahle KW, Heys SD, Rotondo D. Conjugated linoleic acids: are they beneficial or detrimental to health? Prog Lipid Res. 2004;43:553-87.
22. Pariza MW, Hargraves WA. A beef-derived mutagenesis modulator inhibits initiation of mouse epidermal tumors by 7, 12-dimethylbenz [a] anthracene. Carcinogenesis. 1985;6:591-3.
23. Nicolosi RJ, Rogers EJ, Kritchevsky D, Scimeca JA, Huth PJ. Dietary conjugated linoleic acid reduces plasma lipoproteins and early aortic atherosclerosis in hypercholesterolemic hamsters. Artery. 1997;22:266-77.
24. Ha YL, Storkson J, Pariza MW. Inhibition of benzo (a) pyrene-induced mouse forestomach neoplasia by conjugated dienoic derivatives of linoleic acid. Cancer Res. 1990;50:1097-101.
25. Ip C, Chin SF, Scimeca JA, Pariza MW. Mammary cancer prevention by conjugated dienoic derivative of linoleic acid. Cancer Res. 1991;51:6118-24.
26. Houseknecht KL, Vanden Heuvel JP, Moya-Camarena SY, Portocarrero CP, Peck LW, Nickel KP, Belury MA. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty acid fa/fa rat. Biochem Biophys Res Commun. 1998;244:678-82.
27. Cook ME, Miller CC, Park Y, Pariza MW. Immune modulation by altered nutrient metabolism: nutritional control of immune-induced growth depression. Poult Sci. 1993;72:1301-5.
28. Miller CC, Park Y, Pariza MW, Cook ME. Feeding conjugated linoleic acid to animals partially overcomes catabolic responses due to endotoxin injection. Biochem Biophys Res Commun. 1994;198:1107-12.
29. Wedekind KJ, Mansfield HR, Montgomery L. Enumeration and isolation of cellulolytic and hemicellulolytic bacteria from human feces. Appl Environ Microbiol. 1988;54:1530-5.
30. Asanuma N, Kawato M, Hino T. Presence of Butyrivibrio fibrisolvens in the digestive tract of dogs and cats, and its contribution to butyrate production. J Gen Appl Microbiol. 2001;47:313-9.
31. Fukuda S, Furuya H, Suzuki Y, Asanuma N, Hino T. A new strain of Butyrivibrio fibrisolvens that has high ability to isomerize linoleic acid to conjugated linoleic acid. J Gen Appl Microbiol. 2005;51:105-13.
32. Ogimoto K, Imai S. Atlas of rumen microbiology. Tokyo: Japan Scientific Societies Press; 1981. p. 158.
33. Bryant MP. Genus IV. Butyrivibrio Bryant and Small. 1956, 18, emend. Moore, Johnson and Holdeman. 1976, 241. In: Sneath PHA, Mair NS, Sharpe ME, Holt JG, editors. Bergey's manual of systematic bacteriology. Baltimore: Williams and Wilkins; 1986. Volume 2. p. 1376-9.
34. Diez-Gonzalez F, Bond DR, Jennings E, Russell JB. Alternative schemes of butyrate production in Butyrivibrio fibrisolvens and their relationship to acetate utilization, lactate production and phylogeny. Arch Microbiol. 1999;171:324-30.
35. Miyazaki K, Hino T, Itabashi H. Effects of extracellular pH on the intracellular pH and membrane potential of cellulolytic ruminal bacteria, Ruminococcus albus, Ruminococcus flavefaciens, and Fibrobacter succinogenes. J Gen Appl Microbiol. 1992;38:567-73.
36. Hino T, Shimada K, Maruyama T. Substrate preference in a strain of Megasphaera elsdenii, a ruminal bacterium, and its implications in propionate production and growth competition. Appl Environ Microbiol. 1994;60:1827-31.
37. Tudek B, Bird RP, Bruce WR. Foci of aberrant crypts in the colons of mice and rats exposed to carcinogens associated with foods. Cancer Res. 1989;49:1236-40.
38. McLellan EA, Bird RP. Specificity study to evaluate induction of aberrant crypts in murine colons. Cancer Res. 1988;48:6183-6.
39. Hino T, Russell JB. Relative contributions of ruminal bacteria and protozoa to the degradation of protein in vitro. J Anim Sci. 1987;64:261-70.
40. Kurtin WE, Schweainger WH. Assay of β-glucuronidase in bile following ion-pair extraction of pigments and bile acids. Anal Biochem. 1985;147:511-6.
41. Bird RP, Good CK. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett. 2000;112-113:395-402.
42. Kalmokoff ML, Teather RM. Isolation and characterization of a Bacteriocin (Butyrivibriocin AR10) from the ruminal anaerobe Butyrivibrio fibrisolvens AR10: Evidence in support of the widespread occurrence of bacteriocin-like activity among ruminal isolates of B. fibrisolvens. Appl Environ Microbiol. 1997;63:394-402.
43. Weisburger JH. Colon carcinogens: their metabolism and mode of action. Cancer. 1971;28:60-70.
44. Celik C, Lewis DA, Mittleman A. Induction of colon mucosal β-glucuronidase production as a mechanism for 1,2-dimethylhydrazine colon carcinogenesis. J Surg Oncol. 1983;24:209-11.
45. Arimochi H, Kataoka K, Kuwahara T, Nakayama H, Misawa N, Ohnishi Y. Effects of β-glucuronidase-deficient and lycopene-producing Escherichia coli strains on formation of azoxymethane-induced aberrant crypt foci in the rat colon. Biochem Biophys Res Commun. 1999;262:322-7.
46. Takada H, Hirooka T, Hiramatsu Y, Yamamoto M. Effect of β-Glucuronidase inhibitor on azoxymethane-induced colonic carcinogenesis in rats. Cancer Res. 1982;42:331-4.
47. Rafter J. Probiotics and colon cancer. Best Pract Res Clin Gastroenterol. 2003;17:849-59.
48. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189-220.
49. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev. 2002;188:9-21.
50. Kiessling R, Bataillon G, Lamon EW, Klein E. The lymphocyte response to primary Moloney sarcoma virus tumors: definition of a non-specific component of the in vitro cellular hyporeactivity of tumor-bearing hosts. Int J Cancer. 1974;14:642-8.
51. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity Int J Cancer. 1975;16:216-29.
52. Smyth MJ, Crowe NY, Takeda K, Yagita H, Godfrey DI. NKT cells - Conductors of tumor immunity? Curr Opin Immunol. 2002;14:165-71.
53. Hirayama K, Rafter J. The role of probiotic bacteria in cancer prevention. Microbes Infect. 2000;2:681-6.